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ABSTRACT  36 
Context: While both overt hyper- and hypothyroidism are known to lead to cognitive impairment, data on 37 
the association between subclinical thyroid dysfunction and cognitive function are conflicting.  38 
Objective: To determine the risk of dementia and cognitive decline associated with subclinical thyroid dys-39 
function among prospective cohorts. 40 
Data Sources: Search in MEDLINE, EMBASE until November 2014. 41 
Study Selection: Two physicians identified prospective cohorts that assessed thyroid function and cognitive 42 
outcomes (dementia; Mini-Mental State Examination, MMSE). 43 
Data Extraction: Data were extracted by one reviewer following standardized protocols and verified by a 44 
second reviewer. The primary outcome was dementia and decline in cognitive function was the secondary 45 
outcome.  46 
Data Synthesis: Eleven prospective cohorts followed 16,805 participants during a median follow-up of 47 
44.4 months. Five studies analyzed the risk of dementia in subclinical hyperthyroidism (n=6410), six in 48 
subclinical hypothyroidism (n=7401). Five studies analyzed MMSE decline in subclinical hyperthyroidism 49 
(n=7895), seven in subclinical hypothyroidism (n=8960). In random-effects models, the pooled adjusted RR 50 
for dementia in subclinical hyperthyroidism was 1.67 (95% confidence interval [CI] 1.04-2.69) and 1.14 51 
(95%CI 0.84-1.55) in subclinical hypothyroidism versus euthyroidism, both without evidence of significant 52 
heterogeneity (I2=0.0%). The pooled mean MMSE decline from baseline to follow-up (mean 32 months) 53 
did not significantly differ between subclinical hyper- or hypothyroidism versus euthyroidism.  54 
Conclusions: Subclinical hyperthyroidism might be associated with an elevated risk for dementia, while 55 
subclinical hypothyroidism is not, and both conditions are not associated with faster decline in MMSE over 56 
time. Available data are limited, and additional large, high-quality studies are needed.  57 
  58 
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CONTEXT 59 
The prevalence of subclinical hypothyroidism (SHypo) reaches up to 10% in the elderly population, while 60 
subclinical hyperthyroidism (SHyper) has a prevalence of 2.4%, and 4.3% in the population aged ≥80 61 
years.1,2 SHypo is biochemically defined as elevated serum thyroid-stimulating hormone (TSH, thyrotropin) 62 
levels, but free thyroxin (fT4) levels within laboratory reference ranges3, SHyper is defined as decreased 63 
serum TSH concentrations and normal fT4 and fT3 levels. The subclinical forms of thyroid dysfunction have 64 
previously been associated with increased risk of heart failure and coronary heart disease.4-6 Furthermore, 65 
SHyper may negatively influence bone and mineral metabolism.7  66 
While both overt hyper- and hypothyroidism are known to lead to cognitive impairment and clinical guide-67 
lines recommend screening for thyroid dysfunction among patients with cognitive disorders8, data on the 68 
association between subclinical thyroid dysfunction (SCTD) and cognitive function remained conflicting. In 69 
the general population, the prevalence of mild cognitive impairment is 3-22%, with a higher prevalence 70 
among adults >70 years (14-18%).9-11 Mild cognitive impairment, a cognitive decline not normal for age but 71 
with essentially preserved functional activities, is believed to be the earliest clinical symptom of cognitive 72 
disorders and may be the stage to intervene with preventive therapies.11,12 The progression rate from cogni-73 
tive impairment to dementia in the general population aged > 65 years is around 6-10% per year.11 SHyper 74 
has also been associated with increased risk of dementia, 13 with one retrospective cohort reporting a hazard 75 
ratio of 1.6 (95% confidence interval [CI] 1.2-2.3) for dementia.14 SHypo might also be associated with 76 
alterations in cognitive function,13,15,16 with one case-control study reporting a nearly 4-fold increase in the 77 
odds ratio of dementia (OR=3.8, 95%CI 1.6-9.1).17  78 
However, data on the association between SCTD and cognitive function are conflicting.18-20  79 
Two recent meta-analyses yielded discrepant findings for SHypo, one showing a significant risk of cogni-80 
tive alteration (composite endpoint of reduced Mini-Mental State Examination (MMSE), Wechsler Memory 81 
Scale-Revised, total memory quotient and Wechsler Adult Intelligence Scale scores) for SHypo individuals 82 
younger than 75 years with an OR of 1.56 (95%CI 1.07-2.27),21 whereas the other found no decline in 83 
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MMSE in SHypo patients aged ≥60 years (pooled estimate [ES] 0.03, 95%CI −0.001–0.07).22 As both me-84 
ta-analyses were limited by pooling heterogeneous study designs (prospective and retrospective data), and 85 
did neither examine the risk of dementia nor cognitive function associated with SHyper, we conducted a 86 
meta-analysis to determine whether SHyper and SHypo were associated with an increased risk of dementia 87 
or decline in cognitive function in prospective cohorts, the gold standard for observational data.  88 
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METHODS 89 
Data sources and Searches 90 
To perform this systematic review, we followed a pre-defined protocol registered on PROSPERO (Record: 91 
CRD42015019819). We conducted a systematic literature search in MEDLINE and EMBASE databases 92 
from inception until November 2014 searching for articles related to SCTD and cognitive decline and de-93 
mentia. The Medical Subject Headings (Mesh) in Ovid MEDLINE included “thyroid disease”, “hypothy-94 
roidism”, “hyperthyroidism”, “thyroid hormones”, “thyrotropin”, “subclinical hyperthyroidism”, “subclini-95 
cal hypothyroidism”, “subclinical dysthyroidism”, “subclinical thyroid”, “cognition”, “dementia”, 96 
“memory”, “Alzheimer”, “cognitive”, “cohort studies”, “cohort”, “controlled clinical trial”, “epidemiologic 97 
methods”, “review”. We applied a cohort filter designed by the British Medical Journal knowledge infor-98 
mation specialists23 but did not use any other filters or restrictions including year limitations or language 99 
restrictions. A similar strategy with similar terms was used for EMBASE. Additionally, we searched the 100 
bibliographies of included articles, as well as key articles in the field, and contacted several authors for un-101 
published subgroup data. 102 
 103 
Study Selection (Figure 1) 104 
Two reviewers (CR, DS) independently screened titles and abstracts of the search results and selected pub-105 
lications. In a second step, the same two reviewers independently evaluated the full-text publications of the 106 
retrieved studies according to the following pre-specified eligibility criteria: prospective cohort studies 107 
among participants ≥18 years, including a SCTD and a euthyroid control group with thyroid function tests 108 
at baseline and assessment of cognitive function during follow-up, with published risk estimates or suffi-109 
cient information to calculate them. We excluded studies examining solely participants with overt thyroid 110 
disease. Disagreements were resolved by an independent third author (NR). SHyper was defined as de-111 
creased or undetectable TSH and normal fT4, and SHypo as elevated TSH and normal fT4. Cohort-specific 112 
TSH- and fT4-cutoff levels were used to determine thyroid status. For dementia definition, we accepted all 113 
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validated assessments of memory and cognitive function, and did not exclude studies that reported other 114 
scales than MMSE. For our analyses, we also collected information on clinical dementia (Supplement ta-115 
ble 1). Additionally, we gathered data on MMSE results at baseline and follow-up visits. Studies were in-116 
cluded if they provided information on either dementia or MMSE outcomes, or both. 117 
 118 
Data Extraction and Quality Assessment 119 
Standardized data extraction forms were used to collect information from the included cohorts concerning 120 
patient characteristics, thyroid hormone levels, and scales for tests or criteria used to define memory func-121 
tion, dementia or Alzheimer’s disease (AD). Data were extracted by one reviewer (CR) and verified by a 122 
second independent reviewer (DS). Discrepancies were solved by a third author (NR). Two reviewers (CR, 123 
DS) independently assessed study quality using key indicators of cohort study quality24,25: origin of popula-124 
tion (convenience versus population-based, the latter defined as a random sample of the general population), 125 
methods of outcome ascertainment and adjudication (considered as adequate if in each potential case per-126 
formed by an expert panel blinded regarding the thyroid status and following defined outcome criteria), 127 
completeness of follow-up, assessment of the proportional hazard assumption and adjustment for confound-128 
ers.  129 
 130 
Data Synthesis and Statistical Analysis 131 
We performed four main analyses on the association of 1) subclinical hyperthyroidism and dementia, 2) 132 
subclinical hypothyroidism and dementia, 3) subclinical hyperthyroidism and MMSE and 4) subclinical 133 
hypothyroidism and MMSE. We expressed the estimates of the association between SCTD (i.e. SHyper or 134 
SHypo) and outcomes as risk ratios (RR) for dementia or as between-group differences in mean changes 135 
from baseline for MMSE scores (MD). Only prospective data were analyzed. A RR>1 indicates a higher 136 
risk of an event in SCTD compared to euthyroids and a MD>0 indicates higher decline of MMSE in SCTD 137 
compared to euthyroids. To account for the different lengths of follow-up time across studies, we standard-138 
ized MD per 1 year unit. We used most adjusted estimates provided by the studies as primary analysis. We 139 
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used an inverse variance random-effects meta-analysis to pool estimates across studies. Estimates of the 140 
association between SCTD and dementia were pooled on a log scale and latter exponentiated to be reported 141 
as RR. To evaluate heterogeneity across the studies, we used the Q statistic with a conservative p-value of 142 
0.10.26 Furthermore, we calculated the I2 statistic, indicating the proportion of variability in estimates of 143 
effects across studies that is not due to chance alone (<25% low, 25-75% increasing, >75% high heteroge-144 
neity between studies).24 We visually evaluated publication bias through funnel plots and, statistically, with 145 
the Egger’s test.27,28 To explore the sources of heterogeneity, we conducted several sensitivity analyses. Due 146 
to the small number of studies in each group, subgroup analysis with interaction tests could not be meaning-147 
fully performed. All P-values were two-sided. All analyses were conducted using STATA software, version 148 
13.1 (College Station, Texas).   149 
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RESULTS 150 
Study Selection  151 
Of the 1505 reports initially identified, 1471 remained after removing duplicates. We excluded 1435 records 152 
on the basis of their abstracts and 25 after full text examination (Figure 1). Eleven studies met pre-specified 153 
eligibility criteria and were included in the analyses. Among those, 3 studies provided information on both 154 
dementia and MMSE outcomes (Supplement Table 1, Section A), 4 studies reported information on de-155 
mentia outcomes only (Supplement Table 1, Section B), and 4 assessed MMSE outcomes only (Supple-156 
ment Table 1, Section C). The agreement among the reviewers was 98.63% for the first screen of abstracts 157 
(κ=0.75) and 89.74% for the full-text search (κ=0.71). 158 
 159 
Study Characteristics 160 
Eleven cohorts reported data on 16,805 participants (Table 1). Two cohorts only included men.29,30 Mean 161 
age was 70 years or higher, except for one study.31 The follow-up time ranged from 12 to 152 months (me-162 
dian follow-up 44.4 months). Eight cohorts excluded participants treated with thyroid hormones or medica-163 
tions altering thyroid hormone levels, while three excluded the participants taking thyroid hormones or thy-164 
roid altering medication in sensitivity analysis.32-34  165 
 166 
Description and Quality of Studies  167 
The quality of studies was heterogeneous. Nine cohorts were population-based and two were convenience 168 
samples (Supplement Table 1). All the cohorts used third generation TSH assays, except one using second 169 
generation tests and one that did not report test details.35,36 Four studies had a formal adjudication committee 170 
for dementia diagnosis.29-32 Seven studies provided information on attrition during follow-up.20,29,30,32,33,36,37 171 
Six studies provided information on non-violation of the proportional hazard assumption.29,30,33,34,37,38 All 172 
studies reported adjusted data with various confounders, except one study that provided us unadjusted 173 
data.32 174 
 175 
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Subclinical Hyperthyroidism and Dementia  176 
Among five cohorts analyzing the association between SHyper and dementia (n=6410, 329 cases of demen-177 
tia, mean follow-up 68.3 months),29-31,37,38 the pooled risk ratio [RR] of dementia was 1.67 (95%CI 1.04-178 
2.69, I2=0.0%, p for heterogeneity=0.82) among SHyper patients compared with euthyroidism (Figure 2). 179 
Sensitivity analyses (Table 2) excluding one study with a convenience-based sample, one study that fol-180 
lowed both patients with and without thyroid hormone replacement, or studies without or not reported for-181 
mal adjudication for dementia, yielded similar results. As the Framingham study only analyzed the relation-182 
ship with dementia using TSH tertiles (highest tertile: TSH 1.9-9.9 mU/L) and did not measure fT4,34 we 183 
added this study in a sensitivity analysis and found comparable results. A sensitivity analysis excluding 475 184 
overlapping patients between two cohorts31,38 yielded similar results; we did not include these data in the 185 
main analysis, as they examined different follow-up duration and were not based on peer-reviewed pub-186 
lished results (the investigators sent us these data separately). The relationship between SHyper and AD was 187 
assessed by three studies only (n=3186, 108 AD cases, mean follow-up 75.0 months).30,31,38 The pooled RR 188 
for AD was 1.67 (95%CI 0.79-3.51, I2=16.8%, p for heterogeneity=0.30).  189 
 190 
Subclinical Hypothyroidism and Dementia  191 
Among six studies analyzing the relationship between SHypo and dementia (n=7401, 416 cases of demen-192 
tia, mean follow-up 64.6 months),29-32,37,38 the pooled RR for dementia was 1.14 (95%CI 0.84-1.55, 193 
I2=0.0%, p for heterogeneity=0.49) (Figure 2). No individual study showed a statistically significant asso-194 
ciation. Sensitivity analyses (Table 2) excluding a study with a convenience-based sample, studies with 195 
TSH cut-off <4.5mU/l and potentially including individuals in the euthyroid range, two studies that fol-196 
lowed both patients with and without thyroid hormone replacement, studies without or not reported formal 197 
adjudication process for dementia, one study with additional unadjusted data, or 475 overlapping partici-198 
pants between two cohorts31,38 yielded similar results. The addition of the Framingham study34 to the main 199 
analysis yielded similar results. Four studies analyzed the relationship between SHypo and AD (n=3823, 200 
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151 AD cases, mean follow-up 69.36 months).30-32,38 The pooled RR for AD was 0.95 (95%CI 0.52-1.71, 201 
I2=0.0%, p for heterogeneity=0.89). 202 
 203 
Subclinical Hyperthyroidism and MMSE  204 
Among five studies reporting change in MMSE among participants with SHyper (n=7895, mean follow-up 205 
33.6 months),20,31,33,36,37 the pooled mean MMSE decline in cognitive function per year was 0.01 points dif-206 
ference from baseline (95%CI -0.14-0.15; I2=23.5%, p for heterogeneity=0.27; Supplement Figure 1). 207 
Results remained similar after excluding one study using a convenience-based sample or one study that 208 
followed both patients with and without thyroid hormone replacement (Supplement Table 2). Because the 209 
results of the main analyses between SHyper and dementia did not seem concordant with the results of the 210 
meta-analysis looking at the decrease of MMSE in SHyper participants, we undertook a sensitivity analysis 211 
including the two studies examining the relationship of SHyper and both MMSE and dementia31,37, which 212 
also showed no larger decline of MMSE among SHyper. 213 
 214 
Subclinical Hypothyroidism and MMSE  215 
Among seven studies reporting change in MMSE in SHypo (n=8960; mean follow-up 32.2 months),20,31-216 
33,35-37 pooled mean MMSE per year declines did not significantly differ between SHypo and euthyroid 217 
groups (ES 0.01 points difference from baseline, 95%CI -0.10-0.12, I2=27.6%, p for heterogeneity=0.22; 218 
Supplement Figure 1). Sensitivity analyses (Supplement Table 2) excluding one study with a conven-219 
ience-based sample, studies using TSH cut-offs <4.5mU/l, one study that followed both patients with and 220 
without thyroid hormone replacement, one study that might have subclinical hyperthyroid participants in the 221 
control group,35 or one study using unadjusted data yielded similar results. 222 
 223 
Publication bias 224 
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Both graphical inspection and Egger’s tests indicated little evidence of publication bias for all associations, 225 
although the number of available studies was small (Supplement Figure 2).39  226 
  227 
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DISCUSSION AND CONCLUSION  228 
In this meta-analysis of 11 prospective cohorts, we found that SHyper, but not SHypo, might be associated 229 
with an elevated risk for dementia, while decline in MMSE over time was minimal for both conditions. 230 
SHyper showed also a similar pattern of higher risk for AD. Results for the association between SHyper and 231 
dementia remained similar when we pooled higher quality studies in sensitivity analysis, such as studies 232 
with formal adjudication process for the outcome assessment or population-based studies. 233 
Our results for SHyper and risk for dementia are consistent with a non-systematic literature review summa-234 
rizing results from 13 cross-sectional or case-control, and 10 cohort studies that found supportive evidence 235 
of an association between SHyper and cognitive impairment or dementia.40 Of these 10 cohort studies, four 236 
did not meet the eligibility criteria for our systematic review: one due to missing subgroups of thyroid dys-237 
function41, two analyzed only euthyroid participants42,43 and one had a retrospective design14. Several other 238 
individual studies reported an association between SHyper and an elevated risk for dementia as well14,44,45: a 239 
retrospective nested case-control study including 2004 patients with SHyper reported a hazard ratio for de-240 
mentia of 1.79 (95%CI 1.28-2.51), and a cross-sectional study found a positive association between SHyper 241 
and dementia in 1276 participants (33 with SHyper) aged >65 years (OR for dementia 4.1, 95%CI 1.3-242 
13.1).14,44 Van Osch et al prospectively studied 178 patients with AD and 291 community-dwelling controls 243 
without objective cognitive impairment, and found an adjusted OR for AD of 2.36 (95%CI 1.19-4.67) in 244 
participants in the lowest (TSH<1.3mU/l) versus highest TSH tertile (TSH>2.1mU/l).45 Another population-245 
based prospective cohort of 313 elderly adults with normal TSH that found that those with a decline of cog-246 
nitive dysfunction had a mean TSH of 1.78mU/l, while those without decline had a mean TSH of 2.24mU/l 247 
(p=0.001).46  248 
 249 
Our findings might be consistent with the hypothesis that SHyper increases the risk of dementia, although 250 
decline in MMSE over time did not differ between SHyper and euthyroidism. In our meta-analysis, only 251 
two out of 11 studies published results on both dementia and MMSE in SHyper. Analyzing only these two 252 
studies showed no larger decline of MMSE among participants with SHyper. This discrepancy might be 253 
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explained by several factors: the length of follow-up of studies on SCTD and dementia was twice the dura-254 
tion of studies on SCTD and MMSE (mean follow-up time 66 vs. 33 months), different population investi-255 
gated, the modest sensitivity of MMSE as a diagnostic tool (79%)47,48, as well as for detecting mild cogni-256 
tive impairment and subtle changes in specific cognitive domains, and the multimodal approach needed to 257 
diagnose dementia.49 Furthermore, different scores were used as gold standard depending on the type and 258 
version of diagnostic criteria (supplement table 1). Factors increasing the plausibility of the association 259 
between SHyper and dementia were that results remained similar when we pooled higher quality studies in 260 
sensitivity analysis, such as studies with formal adjudication process for the outcome assessment or popula-261 
tion-based studies, and that SHyper also showed a pattern of higher risk for AD. However, higher quality 262 
studies are needed. 263 
 264 
Several pathways could explain the association of thyroid dysfunction with cognition and dementia. Thy-265 
roid hormone has distinct effects on the cardiovascular system and thyroid dysfunction has been associated 266 
with several cardiovascular risk factors, including hypertension, dyslipidemia and atrial fibrillation.4,6 In 267 
turn, these cardiovascular risk factors are associated with a higher risk of dementia and Alzheimer’s Dis-268 
ease.50 Most studies included in our meta-analysis adjusted for cardiovascular risk factors. However, the 269 
number and type of variables that were adjusted for differed for each study. Other explanations for the asso-270 
ciation include direct effects of thyroid hormone, such as neurotoxicity and altered gene expression in 271 
pathways relevant for dementia. The exact pathophysiological link between thyroid dysfunction and demen-272 
tia remains unclear and requires more research.  273 
 274 
Recently, two meta analyses on SHypo and cognitive impairment were published, yielding discrepant re-275 
sults.21,22 The first review included 13 studies and found a significant higher risk for cognitive alteration 276 
(composite endpoint of incidence or prevalence of dementia or difference in MMSE, Wechsler Adult Intel-277 
ligence scale and Wechsler Memory-Revised score) in SHypo individuals younger than 75 years (OR 1.56; 278 
95%CI 1.07-2.27, p=0.02), and for dementia (OR 1.81; 95%CI 1.43-2.28, p<0.01).21 However, the authors 279 
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pooled different designs (cross sectional, case-control, cohort studies), used a composite endpoint of clinical 280 
events and scales as primary outcome, and found a significant risk for the primary endpoint only in subclin-281 
ical hypothyroid individuals younger than 75 years. As results were calculated on the basis of mean age, 282 
without availability of individual patient data, they may have been subject to potential aggregation bias 283 
(ecological fallacy).24,51 Contrary to that meta-analysis, all studies in our meta-analysis but one (included 284 
only in a sensitivity analysis) measured fT4 to define SCTD. The second meta-analysis analyzed 15 studies 285 
(9 cross-sectional, 6 prospective cohort studies) and found no association between SHypo and decline in 286 
cognitive function among people aged > 60 years (cross-sectional analysis: pooled ES for MMSE −0.01 287 
points difference from baseline [95%CI −0.09-0.08]; prospective analysis, pooled MMSE change: 0.03 288 
[95%CI −0.001-0.07] p=0.055, with heterogeneity [I2] of <0.001%),22 which is consistent with our findings. 289 
In comparison to these two meta-analyses, we included only prospective cohorts (n=11) allowing us to re-290 
duce the bias that could arise due to differing study designs. To make literature search broad enough, we 291 
excluded studies examining solely participants with overt thyroid disease but added no other exclusion cri-292 
teria. 293 
Two small placebo controlled trials (n=89; n=94) found no evidence that treatment of SHypo with levothy-294 
roxine was associated with improved cognitive function.18,52 However, these trials had several limitations. 295 
In the trial by Parle et al,52 recruitment was based on a single thyroid function test, so that euthyroid partici-296 
pants with transiently elevated TSH may have been included (50% in the placebo group were euthyroid at 297 
12 months), which may have underpowered the trial to detect an effect of hormone replacement.52 Thyroxin 298 
substitution lasted only for 12-months, which may have been too short to affect cognitive function. In the 299 
trial by Jorde et al,18 one third of participants did not attend follow-up. Because of numerous exclusion cri-300 
teria, the study population was unusually healthy, with 57% of the participants having a TSH value between 301 
3.50 and 4.99mU/l, so that it probably included many euthyroid participants. The ongoing TRUST (Thyroid 302 
Hormone Replacement for Subclinical Hypothyroidism) trial (ClinicalTrials.gov: NCT01660126) may clar-303 
ify whether treatment with levothyroxine in SHypo is associated with better cognitive outcomes over time.53 304 
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There are several strengths of our meta-analysis. By combining the results of 11 prospective cohorts, we 305 
analyzed a total of 432 cases of dementia and 160 cases of AD in more than 15,000 participants. By con-306 
tacting several authors of these studies, we obtained additional data that allowed us to derive more uniform 307 
subgroup and sensitivity analyses. In comparison to the two other meta-analyses,21,22 our results are less 308 
prone to bias due to pooling of heterogeneous study design and quality, because we only included prospec-309 
tive cohorts. We also conducted a detailed literature search in several electronic databases with as few limi-310 
tations as possible in order to retrieve the maximum number of studies available on the topic, and were able 311 
to include a larger number of prospective cohorts than previous meta-analyses.21,22  312 
 313 
Our meta-analysis has also several limitations. Except for two studies30,35, studies only examined Cauca-314 
sians, limiting the generalizability to other populations. All studies were performed in participants with a 315 
mean age >65 years and the time of follow-up was relatively short, ranging between 12 and 70.8 months 316 
(152.4 months in the Framingham Study,34 added in a sensitivity analysis). All but two studies 20,33 assessed 317 
thyroid function tests only at baseline, which is a limitation of most previously published large cohort stud-318 
ies on the risks of thyroid dysfunction54,55. Some participants with SCTD at baseline may have normalized 319 
to euthyroidism or progressed to overt thyroid disease over time. Regarding the elderly participants in the 320 
included studies, we cannot exclude a certain degree of overdiagnosis of SHypo due to the physiological 321 
rise of TSH towards upper limits during normal ageing.56 All these non-differential misclassification of 322 
thyroid status might bias the results towards no difference. The limited sensitivity of MMSE for detecting 323 
subtle changes in specific cognitive domains57 may further limit our ability to detect a possible decline in 324 
cognitive function. A meta-analysis of observational studies requires cautious interpretation of the results 325 
and potential biases, and confounding and heterogeneity must be carefully investigated.58,59 The quality of 326 
the incorporated studies was variable. We performed several sensitivity analyses to address differences be-327 
tween the studies, as recommended,58 although they should be interpreted with caution given the small 328 
number of studies. In study level meta-analysis, interpretation of subgroup data should be performed with 329 
caution. Because of the small amount of studies, no meaningful subgroup analysis could be performed. 330 
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There are multiple confounders for cognitive decline and dementia, the most important is age, others are 331 
depression/mood or cardiometabolic risk factors. All cohorts adjusted for age and several other confound-332 
ers, but there was heterogeneity in the choice of confounders, which may lead to residual confounding. Bias 333 
in the selection of included studies cannot be excluded. To limit selection bias, we conducted a detailed 334 
literature search in several electronic databases with broad inclusion. We performed graphical and statistical 335 
assessment to assess selective reporting, but these analyses were not very sensitive considering the small 336 
number of studies included.25,28 Although included cohorts enrolled community-dwelling adults in ambula-337 
tory visits, who are therefore less likely to have an acute disease, some participants with non-thyroidal ill-338 
ness may have been analyzed. Included studies addressed this problem differently: Two repeatedly meas-339 
ured thyroid values20,33, one assessed and adjusted for rT3 (reverse triiodothyronine)38, and others adjusted 340 
for comorbidities. We cannot exclude that some participants had nonthyroidal illness. 341 
What are the potential clinical and research implication of our findings? Our data suggest that SHyper might 342 
represent a potentially treatable risk factor for dementia. Given the relatively high prevalence of both SCTD 343 
and cognitive dysfunction in the aging population, even a modest increase of dementia incidence among 344 
individuals with SCTD might have public health implications. Data on benefit of SCTD treatment are 345 
scarce, therefore current guidelines do not recommend treatment for most adults with mild SCTD (serum 346 
TSH 0.1-0.45mU/l or 4.5-10.0mU/l).60,61 Large randomized controlled trials are required to assess the effi-347 
cacy of treatment in SCTD associated with dementia. For SHypo, the ongoing TRUST (Thyroid Hormone 348 
Replacement for Subclinical Hypothyroidism) trial (ClinicalTrials.gov: NCT01660126) will clarify this 349 
issue.62 350 
 351 
In summary, our systematic review and meta-analysis indicates that SHyper, but not SHypo, might be asso-352 
ciated with a modestly elevated risk of dementia. Neither SHyper nor SHypo were significantly associated 353 
with a faster decline in MMSE over time, as compared to euthyroidism. Available data were limited, and 354 
additional large, high-quality prospective cohort studies are needed.  355 
 356 
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Table 1. Description of Included Studies for the Effect of Subclinical Thyroid Dysfunction on Dementia/Mini-Mental State Examination 
(MMSE) 
Study, 
Year of publication Population Women 
Mean age;  
SD 
Follow-
up time Age 
TSH cutoff level 
(mU/l) 
fT4 
measured 
Thyroid 
hormone 
recipients 
excluded? 
 
N % years months 
min-max. 
years SHypo SHyper 
  Rotterdam,31 2000§ 1843 61.9 68.8; 7.5 25.2 55-93 > 4.0 < 0.4 yes yes 
Leiden 85-Plus Study,33 2004 558 66.0 85.0; 0.0 44.4 85 > 4.8 < 0.3 yes in SA 
Rotterdam Scan,38 2006 1077 51.2 72.3†; 7.4 66.0 60-90 > 4.3 < 0.4 yes yes 
Health Ageing,36 2008 1047 51.0 73.6; 6.2 24.0 64-94 > 4.8 < 0.3 yes yes 
Framingham,34 2008‡ 1864 59.0 71.0; 7.0 152.4  ‡ ‡ no in SA 
HAAS,30 2009 665 0.0 78.0 56.4 71-93 > 4.3 < 0.4 yes yes 
Japanese Study,35 2010 229 65.0 80.9; 4.7 12.0 
 
> 4.0 NR yes yes 
Conselice,32 2012§ 660 52.9 73.3; 6.0 45.6 65-91 > 4.5 < 0.45 yes in SA 
HIMS,29 2012 3401 0.0 76.8; 3.5 70.8† 70-89 > 4.0 < 0.4 yes yes 
PROSPER,20 2013 5154 49.4 75.0 38.4 80-82 > 4.5 < 0.45 yes yes 
OCTABAIX,37 2014|| 307 54.6 85.0; 0.0 36.0 85 > 5 < 0.25 yes yes 
Abbreviations: Conselice = Conselice Study of Brain Ageing; Framingham = The Framingham Study; fT4 = free thyroxine; HAAS = Honolulu-Asia Aging Study; 
Health Ageing = Health Ageing Study; HIMS = The Health in Men Study; Japanese Study = Cognitive function with subclinical hypothyroidism in elderly people 
without dementia: One year follow up; Leiden 85+ = Leiden 85-plus Study; NR = not reported; OCTABAIX = OCTABAIX Study; PROSPER = The PROSPER 
Study; Rotterdam Scan = Rotterdam Scan Study; Rotterdam = The Rotterdam Study; SA = sensitivity analysis; SHyper = subclinical hyperthyroidism; SHypo = 
subclinical hypothyroidism; TSH = thyrotropin.  
† median 
‡ The Framingham Study did not use TSH cut-offs for SCTD, but tertiles: tertile 1: 0.1-1.08mU/l for women, 0.10-0.90mU/l for men; tertile 2: 1.10-2.03mU/l for 
women, 0.99-1.80mU/l for men; tertile 3: 2.10-9.90mU/l for women, 1.09-9.90mU/l for men. Therefore, this study could not be included in the meta-analysis 
but was added to a sensitivity analysis.  
§ Due to additional unpublished data provided by the authors, the studies could be incorporated in the meta-analysis on SCTD and MMSE; unadjusted data. 
|| Due to additional unpublished data provided by the authors, the study could be incorporated in the meta-analysis on SCTD and dementia. 
Supplement Table 1: Quality Assessment of Included Studies 
Study Population, setting 
Assessment of dementia or 
Alzheimer's Disease 
Formal 
adjudica-
tion for 
dementia 
or Alzhei-
mer’s 
Disease 
Blinding 
of study 
investiga
-tors 
regardin
g TSH 
Blinding 
of 
patients 
regardin
g TSH 
Loss of FUP (reasons 
for incompleteness) 
TSH 
assess
ment 
TSH 
assay Adjustment for potential confounders 
A. Studies that provided information on both dementia and MMSE outcomes 
Rotterdam,31 
2000 
population-
based, 
ambulatory / 
subjects in 
institutions 
D: DSM-III-R (3-step-
screening: 1. MMSE (<26), 
GMSS (<0); 2. CAMDEX; 3. 
Neurologist, 
Neuropsychologist, Brain 
Image); AD: NINCDS-
ADRDA 
yes NR NR NR 
 
 
 
 
BL 
3rd 
 
Age, sex, atrial fibrillation, education (years), 
cigarette smoking (never, former, current), 
depressive symptoms, APOE 
Conselice,32 
2012 
population-
based, 
ambulatory 
D: DSM-IV (Multi step 
screening: 1. Interview, IADL, 
GDS, MMSE (<24; >9), 
neurological examination, 
blood test; 
2.Neuropsychological testing 
with Mental Deterioration 
Battery, Prose Memory Test); 
AD: NINCDS-ADRDA 
yes no NR 
Exclusion at BL: 
dementia [60], MCI 
[71], unclassifiable 
cognitive status [22],at 
BL or FUP ; missing 
laboratory data [32], 
missing information 
about cognitive status at 
FUP [82], due to death 
[82], refusal [52] or 
failure to be traced 
BL 3rd * 
OCTA-
BAIX,37 
2014 
population-
based, 
ambulatory 
NR 
(Assessments: BI, BADL, LI; 
MMSE <23/35pts; Mini 
Nutritional Assessment, Gait 
Rating Scale, QoL-VAS, CS) 
NR NR NR 
102 (death during FUP 
[51], from the 256 
surviving patients only 
205 with geriatric 
assessment, reason 
unclear) 
BL 3rd 
**, Sex, education, marital status, 
cardiovascular risk factors such as treatment 
for high blood pressure above 140/90, 
diabetes mellitus, dyslipidemia, heart failure, 
medication, prevalence for stroke or dementia, 
number of drugs prescribed 
B. Studies that provided information on dementia outcomes 
Rotterdam 
Scan,38 2006 
population-
based, 
ambulatory / 
subjects in 
institutions 
D: DSM-III-R 
(MR for all study subjects, then 
three step protocol for 
screening: 1. Screening MMSE 
(<26) and GMSS (>0); 2. 
CAMDEX; 3. 
Neuropsychological 
testing);AD: NINCDS-ADRDA 
NR NR NR NR BL 3rd  
Age, sex, educational level, depressive 
symptoms, cigarette smoking, cardiac 
medication, beta-blockers, systemic 
corticosteroid use, atrial fibrillation, diabetes 
mellitus, BMI; total cholesterol and HDL 
levels, creatinine, homocysteine level, T3/rT3, 
TPO-AB 
  
Study Population, setting 
Assessment of dementia or 
Alzheimer's Disease 
Formal 
adjudica-
tion for 
dementia 
or Alzhei-
mer’s 
Disease 
Blinding 
of study 
investiga
-tors 
regardin
g TSH 
Blinding 
of 
patients 
regardin
g TSH 
Loss of FUP (reasons 
for incompleteness) 
 
 
TSH 
assess
ment 
TSH 
assay  Adjustment for potential confounders 
B. Studies that provided information on dementia outcomes 
HAAS,30 
2009 
population-
based, 
ambulatory 
D: DSM-III-R (Multi step 
protocol: 1. CASI; 2. CERAD; 
3. Neurologic Exam and 
Interview. In case of Dementia: 
neuroimaging and blood test); 
MMSE derived from CASI. 
AD: NINCDS-ADRDA; 
CERAD 
yes NR NR 
335 (dementia at BL 
[131], death or refusal 
[204]) 
BL 3rd 
Age, age at death (autopsy-study), educational 
level, depressive symptoms, diabetes mellitus, 
smoking status, systolic and diastolic blood 
pressure, use of thyroid medication, thyroid-
altering drugs (incl. beta-blocking agents and 
antiarrhythmics), BMI, biochemical markers 
(albumin, total and HDL cholesterol, APOE). 
HIMS,29 
2012 
convenience
-based, 
ambulatory 
D: ICD-9/10 NR NR NR 
2848 (exclusion due to: 
history of thyroid 
disease [2139], thyroid 
drugs [71], missing data 
[82], hyperthyroidism 
[14], prevalent dementia 
[12], with SMMSE < 24 
[521], fT4 < 9 pmol/l 
[1], fT4 > 25pmol/l [8]) 
BL 3rd 
Age, BMI, smoking-status, education, 
SMMSE, social support, medical 
comorbidities, sensorial impairment 
Framing-
ham,34 2008 
population-
based, 
ambulatory 
D: DSM-IV and Clinical 
Dementia Rating ≥1 and 
symptoms of dementia ≥ 6 
months (Multi step protocol: 
1.Neuropsycho-logical Testing, 
MMSE; 2. Neurological- and 
neuropsychological 
examinations); AD: NINCDS-
ADRDA 
yes NR NR 295 (reason unclear) 
2 
years 
before 
BL 
3rd 
Age, APOE, education level (dichotomized: 
high school completion yes/no), plasma 
homocysteine, current smoking, body-mass 
index, prevalent stroke, atrial fibrillation 
C. Studies that provided information only on MMSE outcomes 
Leiden 85-
Plus Study, 
33 2004 
population-
based, 
ambulatory 
no assessment of dementia or 
AD, only MMSE outcomes 
reported 
dementia  
not 
assessed 
NR NR 279 (death [209], refusal [70]) 
 
BL +  
3 year 
FUP 
3rd  
 
**, Sex, self-reported educational level (<6 vs 
> 6 years of education), albumin, CRP, 
MMSE at baseline, subjective health, type 2 
diabetes, myocardial infarction, stroke, 
COPD, arthritis, Parkinson disease 
Health 
Ageing,36 
2008 
population-
based, 
ambulatory 
no assessment of dementia or 
AD, only MMSE outcomes 
reported 
dementia  
not 
assessed 
yes NR 148 
 
BL 2nd 
 
Age, sex, education, mood, baseline MMSE, 
high blood pressure, smoking, history of 
diabetes mellitus, heart attack, stroke, study 
site 
 
Study Population, setting 
Assessment of dementia or 
Alzheimer's Disease 
Formal 
adjudica-
tion for 
dementia 
or Alzhei-
mer’s 
Disease 
Blinding 
of study 
investiga
-tors 
regardin
g TSH 
Blinding 
of 
patients 
regardin
g TSH 
Loss of FUP (reasons 
for incompleteness) 
 
 
TSH 
assess
ment 
TSH 
assay  Adjustment for potential confounders 
C. Studies that provided information only on MMSE outcomes 
Japanese 
Study,35 
2010 
population-
based, 
ambulatory 
no assessment of dementia or 
AD, only MMSE outcomes 
reported 
dementia  
not 
assessed 
NR NR NR BL NR 
Sex, age, BMI, physical status, diabetes 
mellitus, cardiovascular disease, hypertension, 
dyslipidemia, points of BL cognitive function, 
arterial stiffness. 
PROSPER,20 
2013 
convenience
-based, 
ambulatory 
no assessment of dementia or 
AD, only MMSE outcomes 
reported 
dementia  
not 
assessed 
NR NR 
650 (exclusion at BL: 
antithyroid drugs [6], 
levothyroxine[159], 
amiodarone [20], high 
fT4 and high TSH [7], 
low fT4 and low TSH 
[1], overt thyroid 
disease [146], missing 
fT4 [303], missing TSH 
[8]) 
BL + 
at 6 
Mont
h 
3rd Sex, age, education, country, Apo E genotype 
Abbreviations: AD = Alzheimer’s disease; APOE = Apolipoprotein-E Ɛ4 allele status; BADL = Basic Activities of Daily Living; BI = Barthel Index; BL = Baseline; BMI = 
Body mass index; CAMDEX = Cambridge examination for mental disorders of the elderly ; CASI = Cognitive Abilities Screening Instrument; CERAD = Consortium to Establish 
a Registry for Alzheimer Disease battery; Conselice = Conselice Study of Brain Ageing; COPD = Chronic obstructive pulmonary disease; CRP = C-reactive protein; CS = 
Charlson Score; D = dementia; DSM = Diagnostic and Statistical Manual of Mental Disorders; Framingham = The Framingham Study; fT4 = Free thyroxine; FUP = Follow-up; 
GDS = Geriatric Depression Scale; GMSS = Geriatric Mental State Schedule ; HAAS = Honolulu-Asia Aging Study; HDL = High-density lipoproteins; Health Ageing = Health 
Ageing Study; HIMS = The Health in Men Study; IADL = Instrumental Activities of Daily Living; ICD = International Statistical Classification of Diseases and Related Health 
Problems; Japanese Study = Cognitive function with subclinical hypothyroidism in elderly people without dementia: One year follow up; Leiden 85+ = Leiden 85-Plus Study; LI 
= Lawton Index; MCI: Mild cognitive impairment; MMSE = Mini Mental State Exam; NINCDS-ADRDA = National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Disease and Related Disorders Association; NR = Not reported; OCTABIX = OCTABAIX Study; PROSPER = The PROSPER Study; pts = points; 
QoL-VAS = Quality of Life Test Visual Analogue Scale; Rotterdam Scan = Rotterdam Scan Study; Rotterdam = The Rotterdam Study; SA = Sensitivity analysis; SHyper = 
Subclinical hyperthyroidism; SHypo = Subclinical hypothyroidism; SMMSE = Standardized mini mental state exam; TPO-AB = Thyroid peroxidase antibodies; TSH = 
thyrotropin. 
 
* Unadjusted additional data has been used for this meta-analysis. The original study adjusted for age, sex, education, serum cholesterol, Geriatric Depression Scale Score, BMI, 
hypertension, diabetes mellitus, history of cardiovascular disease, plasma total homocysteine. 
** No adjustment for age because of same aged cohort. 
Table 2: Sensitivity Analyses on the Association between Subclinical Thyroid Dysfunction (SCTD) 
and Dementia  
 
RR† 95% CI p for heterogeneity 
N of 
studies 
Subclinical Hyperthyroidism and Dementia 
    Main analysis29-31,37,38 1.67 1.04, 2.69 0.82 5 
Exclusion of one study using a convenience-based sample30,31,37,38 1.73 1.07, 2.80 0.82 4 
Exclusion of one study enrolling patients with and without thyroid 
hormone replacement29,31,37,38  1.73 0.96, 3.11 0.68 4 
Exclusion of studies without formal adjudication30,31  1.86 0.96, 3.62 0.46 2 
Exclusion of overlapping 475 participants from 2 studies 29-31,37,38‡ 1.60 0.92, 2.78 0.82 5 
Main analysis adding the Framingham Study29-31,34,37,38 § 1.46 1.08, 1.97 0.84 6 
 
Subclinical Hypothyroidism and Dementia 
    Main analysis29-32,37,38 1.14 0.84, 1.55 0.49 6 
Exclusion of one study using a convenience-based population30-
32,37,38 1.31 0.91, 1.89 0.65 5 
Exclusion of studies with TSH cut-off <4.5mU/l32,37 1.36 0.91, 2.05 0.59 2 
Exclusion of two studies enrolling patients with and without 
thyroid hormone replacement29,31,37,38 1.14 0.69, 1.90 0.29 4 
Exclusion of studies without formal adjudication process30-32 1.14 0.73, 1.78 0.57 3 
Exclusion of one study with unadjusted data29-31,37,38 1.06 0.71, 1.60 0.39 5 
Exclusion of overlapping 475 participants from 2 studies29-32,37,38 ‡ 1.10 0.80, 1.50 0.66 6 
Main analysis adding the Framingham Study 29-32,34,37,38§ 1.18 0.91, 1.52 0.60 7 
Abbreviations: CI = confidence interval; N = number; RR = risk ratio; SCTD = subclinical thyroid dysfunction; TSH = 
thyrotropin. 
† RR>1 indicates higher risk of an event in SCTD than in euthyroidism. A positive mean difference indicates larger 
decrease in cognitive function in SCTD than in euthyroidism.  
‡ Performed on data additionally provided by the author; we did not include these data in the main analysis, as they 
examined different follow-up duration and were not based on peer-reviewed published results (the investigators sent us 
these data separately) 
§ As the Framingham Study did not use TSH cut-off for SCTD, we compared lowest versus highest tertiles (lowest 
tertile: 0.10-1.08 for women, 0.10-0.90 for men; highest tertile 2.10-9.90 for women, 1.90-9.90 for men).34 
 
Supplement Table 2: Sensitivity Analyses on the Association between Subclinical Thyroid 
Dysfunction and Annualized Mean Change in Mini-Mental State Examination (MMSE) 
 
ES 95% CI p for heterogeneity 
N. of 
studies 
Subclinical Hyperthyroidism and MMSE  
    Main analysis20,31,33,36,37  0.01  -0.14, 0.15 0.27 5 
Exclusion of one study using a convenience-based 
population31,33,36,37  0.06 -0.36, 0.49 0.20 4 
Exclusion of one study enrolling patients with and without 
thyroid hormone replacement20,31,33,37 -0.01 -0.11, 0.09 0.68 4 
Studies indicating results for both MMSE and dementia31,37 -0.09 -0.26, 0.08 0.80 2 
 
Subclinical Hypothyroidism and MMSE 
    Main analysis20,31-33,35-37  0.01 -0.10, 0.12 0.22 7 
Exclusion of one study using a convenience-based population31-
33,35-37  0.06 -0.06, 0.18 0.48 6 
Exclusion of studies with TSH cut-off <4.5mU/l20,32,33,36,37  0.07 -0.13, 0.28 0.09 5 
Exclusion of one study Exclusion of one study enrolling 
patients with and without thyroid hormone replacement20,31-
33,35,37 
-0.01 -0.12, 0.11 0.22 6 
Exclusion of one study with unadjusted data20,31,33,35-37 -0.06 -0.13, 0.01 0.70 6 
Studies indicating results for both MMSE and dementia31,32,37  0.06 -0.14, 0.26 0.18 3 
Exclusion of the Japanese Study20,31-33,36,37†  0.01 -0.11, 0.13 0.16 6 
Abbreviations: MD = mean difference in change from baseline for mini mental state exam score. MD >0 indicates 
higher decline of MMSE in SCTD than in euthyroidism.  
Abbreviations: CI = confidence interval; ES = effect size, defined as annualized mean change in MMSE; MMSE = 
Mini-Mental State Examination; N = number; SCTD = subclinical thyroid dysfunction; TSH = thyrotropin. 
† This study35 was excluded in the sensitivity analysis, because it might have included subclinical hyperthyroid 
participants in the control group.  
  
 
 
 
  
 
 
